Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Johns Hopkins All Children's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT03843528
- Locations
- 🇺🇸
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT03842696
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT03742245
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- miRagen Therapeutics, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03713320
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 21
- Registration Number
- NCT03426891
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 31
- Registration Number
- NCT03382834
- Locations
- 🇺🇸
Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
🇺🇸Cincinnati Clinical Research Site, Cincinnati, Ohio, United States
MIBG With Dinutuximab +/- Vorinostat
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-11-18
- Target Recruit Count
- 45
- Registration Number
- NCT03332667
- Locations
- 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Epigenetic Reprogramming in Relapse/Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-06-24
- Target Recruit Count
- 37
- Registration Number
- NCT03263936
- Locations
- 🇺🇸
National Cancer Institute, Pediatric Oncology Branch, Bethesda, Maryland, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03259503
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 17
- Registration Number
- NCT03212989
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.